Hyperbilirubinemia

Hyperbilirubinemia in Term Neonates
Tanya Oberoi Pandya D.O., M.B.A.&
Vishaan Pandya (Master’s In Colic, PhD in Poopology)
Hyperbilirubinemia in Term Neonates.ppt

Hyperbilirubinemia in Infants
Christine Piper
Hyperbilirubinemia in Infants.ppt

Hyperbilirubinemia
Hyperbilirubinemia-3-2005.ppt

Neonatal Hyperbilirubinemia
Neonatal Hyperbilirubinemia.ppt

Neonatal Hyperbilirubinemia
Hyperbilirubinemia.ppt

Neonatal Hyperbilirubinemia: An Update
Bryan Burke, MD
Neonatal Hyperbilirubinemia: An Update.ppt

Hyperbilirubinemia
Eric Demers, M.D.
Hyperbilirubinemia-2012.ppt

Preterm Infant
Mary L. Dunlap
Preterm Infant.ppt

High Risk Neonates
Presented by Ann Hearn RNC, MSN
HighRiskNeonatesforBB.ppt

Identification of At-risk Newborn
Nancy Pares, RN, MSN
Identification of At-risk Newborn.ppt

High Risk Newborn Nursing Care
D. Ann Currie, RN, MSN
High_Risk_Neonatal_Nursing_Care.ppt

Tyrosine Kinase Inhibitors - Chemotherapy Review Session
Sarah Lentz RPh BCOP
Tyrosine Kinase Inhibitors - Chemotherapy Review Session.ppt

Heme Degradation & Hyperbilirubinemias
Beth A. Bouchard
Heme Degradation & Hyperbilirubinemias.ppt

Blood Incompatibilities and Jaundice
Newbornsatrisk.ppt

Hyperbilirubinemia
Patricia R Chess MD
Hyperbilirubinemia.ppt

Hemolytic Disease of the Newborn, Current Methods of Diagnosis and Treatment
Terry Kotrla, MS,
HDN.ppt

Epidemiology in Gestational Diabetes Mellitus
Dr. Nam-Han Cho
Epidemiology in Gestational Diabetes Mellitus.ppt

Sickle Cell Hepatopathy
Kerry Williams, M.D
Hem/Onc Grand Rounds
Sickle Cell Hepatopathy.ppt

Red Blood Cell Disorders
Amy S. Gewirtz, MD
Red Blood Cell Disorders.ppt

Jaundice
Tad Kim, M.D., Connie Lee, M.D.
Jaundice_Lee.ppt


209 Published articles on Hyperbilirubinemia free access

1. Side effects of phototherapy for neonatal hyperbilirubinemia.
2. Genetic factors in the occurrence of neonatal unconjugated hyperbilirubinemia.
3. Etiological analyses of marked neonatal hyperbilirubinemia in a single institution in taiwan.
4. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.
5. Urinary tract infection and indirect hyperbilirubinemia in newborns.
6. Clofibrate for unconjugated hyperbilirubinemia in neonates: a systematic review.
7. Hyperbilirubinemia and neurodevelopmental outcome of very low birthweight infants: results from the LIFT cohort.
8. A homozygous mutation in UGT1A1 exon 5 may be responsible for persistent hyperbilirubinemia in a Japanese girl with Gilbert's syndrome.
9. Efficacy of phototherapy for newborns with hyperbilirubinemia: a cautionary example of an instrumental variable analysis.
10. Risk assessment and follow-up are the keys to preventing severe hyperbilirubinemia.
11. Systematic follow-up of hyperbilirubinemia in neonates with a gestational age of 35 to 37 weeks.
12. Prevalence of Gilbert syndrome in parents of neonates with pathologic indirect hyperbilirubinemia.
13. Spur cell anemia as a cause of unconjugated hyperbilirubinemia after liver transplantation and its resolution after retransplantation.
14. Prospective validation of a novel strategy for assessing risk of significant hyperbilirubinemia.
15. Hyperbilirubinemia reduces the streptozotocin-induced pancreatic damage through attenuating the oxidative stress in the Gunn rat.
16. Correction of hyperbilirubinemia in gunn rats using clinically relevant low doses of helper-dependent adenoviral vectors.
17. Automated peripheral arteriovenous exchange transfusion for treatment of severe hyperbilirubinemia in neonates.
18. Hyperbilirubinemia in newborns with gestation ≥35 weeks.
19. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis.
20. Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.
21. Relationship between apnea and hyperbilirubinemia in premature infants.
22. Yield of recommended blood tests for neonates requiring phototherapy for hyperbilirubinemia.
23. Putting prevention into practice. Screening of infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy.
24. Screening of infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy: recommendation statement.
25. Indirect hyperbilirubinemia of genetic origin: Case report of Crigler-Najjar syndrome type II.
26. Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension.
27. Hemolysis and hyperbilirubinemia in antiglobulin positive, direct ABO blood group heterospecific neonates.
28. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.
29. Prolonged neonatal hyperbilirubinemia associated with a UGT1A1 gene mutation.
30. Incidence of neonatal hyperbilirubinemia: a population-based prospective study in Pakistan.
31. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.
32. Reduction of severe hyperbilirubinemia after institution of predischarge bilirubin screening.
33. Outcome of neonatal hyperbilirubinemia in a tertiary care hospital in bangladesh.
34. NMDAR expression in the cochlear nucleus and hearing damage in neonatal rats with hyperbilirubinemia.
35. What blood tests to predict severe hyperbilirubinemia in early maternity discharge?.
36. Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus.
37. Glucocorticoid treatment for early postoperative cholangiole cholestasis hyperbilirubinemia after liver transplantation.
38. Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report.
39. Significant weight loss in breastfed term infants readmitted for hyperbilirubinemia.
40. Unconjugated hyperbilirubinemia and early childhood caries in a diverse group of neonates.
41. Metalloporphyrins in the management of neonatal hyperbilirubinemia.
42. Hereditary spherocytosis in neonates with hyperbilirubinemia.
43. Case series of cetuximab monotherapy for patients with pre-treated colorectal cancer complicated with hyperbilirubinemia due to severe liver metastasis.
44. Complex multifactorial nature of significant hyperbilirubinemia in neonates.
45. Single vs. double phototherapy in the treatment of full-term newborns with nonhemolytic hyperbilirubinemia.
46. Does measuring the changes in TcB value offer better prediction of Hyperbilirubinemia in healthy neonates?
47. Hyperbilirubinemia in the newborn infant > or =35 weeks' gestation: an update with clarifications.
48. Screening of infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy: US Preventive Services Task Force recommendation statement.
49. Transcutaneous bilirubin nomogram for prediction of significant neonatal hyperbilirubinemia.
50. Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use.
51. Spectrum and outcome analysis of marked neonatal hyperbilirubinemia with blood group incompatibility.
52. Analysis of transient otoacoustic emissions and brainstem evoked auditory potentials in neonates with hyperbilirubinemia.
53. Targeted suppression of heme oxygenase-1 by small interference RNAs inhibits the production of bilirubin in neonatal rat with hyperbilirubinemia.
54. Does Ibuprofen increase neonatal hyperbilirubinemia?
55. Effect of albumin administration prior to exchange transfusion in term neonates with hyperbilirubinemia--a randomized controlled trial.
56. Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice.
57. Hyperbilirubinemia in normal healthy donors.
58. Hyperbilirubinemia and transcutaneous bilirubinometry.
59. Incidence and causes of neonatal hyperbilirubinemia in a center of Catania.
60. Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia.
61. Effects of hyperbilirubinemia on distortion product otoacoustic emission, auditory brainstem response and mismatch negativity in guinea pigs.
62. ABO hemolytic disease and developing of significant hyperbilirubinemia in term newborns: early predictive factors.
63. Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy.
64. Interaction of hemolysis and hyperbilirubinemia on neurodevelopmental outcomes in the collaborative perinatal project.
65. No association between hyperbilirubinemia and attention-deficit disorder.
66. Hyperbilirubinemia and language delay in premature infants.
67. Failure to predict hemolysis and hyperbilirubinemia by IgG subclass in blood group A or B infants born to group O mothers.
68. Donor blood glucose 6-phosphate dehydrogenase deficiency reduces the efficacy of exchange transfusion in neonatal hyperbilirubinemia.
69. A randomized trial of aggressive versus conservative phototherapy for hyperbilirubinemia in infants weighing less than 1500 g: Short- and long-term outcomes.
70. Re: Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks' gestation) - Summary. Paediatr Child Health 2007;12(5):401-7.
71. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks' gestation) - Summary.
72. Evaluation of the BiliChek noninvasive bilirubin analyzer for prediction of serum bilirubin and risk of hyperbilirubinemia.
73. Variations in the UDP-glucuronosyltransferase 1A1 gene for the development of unconjugated hyperbilirubinemia in Taiwanese.
74. Neonatal hyperbilirubinemia: don't let glucose-6-phosphate dehydrogenase deficiency off the hook.
75. Risk factors for severe hyperbilirubinemia among infants with borderline bilirubin levels: a nested case-control study.
76. Hyperbilirubinemia diminishes respiratory drive in a rat pup model.
77. A comparison of alternative risk-assessment strategies for predicting significant neonatal hyperbilirubinemia in term and near-term infants.
78. Postoperative hyperbilirubinemia and graft outcome in living donor liver transplantation.
79. Transcutaneous bilirubinometry: important method in the evaluation of newborns with hyperbilirubinemia.
80. Comments on seven novel mutations of the UGT1A1 gene in patients with unconjugated hyperbilirubinemia by D'Apolito et al.
81. Prevention of severe neonatal hyperbilirubinemia in healthy infants of 35 or more weeks of gestation: implementation of a systems-based approach.
82. Coombs' testing and neonatal hyperbilirubinemia.
83. Coombs' testing and neonatal hyperbilirubinemia.
84. Marked hyperbilirubinemia associated with the heme oxygenase-1 gene promoter microsatellite polymorphism in a boy with autoimmune hemolytic anemia.
85. Seven novel mutations of the UGT1A1 gene in patients with unconjugated hyperbilirubinemia.
86. Antioxidant vitamins and hyperbilirubinemia in neonates.
87. Treatment of hyperbilirubinemia with blood purification in China.
88. Hyperbilirubinemia after extracorporeal circulation surgery: a recent and prospective study.
89. Effect of predischarge bilirubin screening on subsequent hyperbilirubinemia.
90. Surveillance of severe neonatal hyperbilirubinemia: a view from south of the border.
91. Incidence and causes of severe neonatal hyperbilirubinemia in Canada.
92. Effect of prophylactic phototherapy on neonatal hyperbilirubinemia of prematures.
93. Randomized controlled trial of compact fluorescent lamp versus standard phototherapy for the treatment of neonatal hyperbilirubinemia.
94. Amphotericin B-associated hyperbilirubinemia: case report and review of the literature.
95. Abuse of casein hydrolysate formulas for treating infants with severe hyperbilirubinemia.
96. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia: genetic screening is unnecessary.
97. The changing face of race: risk factors for neonatal hyperbilirubinemia.
98. Tienilic acid enhances hyperbilirubinemia in Eisai hyperbilirubinuria rats through hepatic multidrug resistance-associated protein 3 and heme oxygenase-1 induction.
99. Management of neonatal hyperbilirubinemia: pediatricians' practices and educational needs.
100. Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors.
101. Computerized decision-making assistance for managing neonatal hyperbilirubinemia.
102. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.
103. Proton magnetic resonance spectroscopy of the anterior cingulate gyrus, insular cortex and thalamus in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome).
104. Value of bilirubin oxidase and its mutants in the diagnosis of hyperbilirubinemia.
105. Clinical (video) findings and cerebrospinal fluid neurotransmitters in 2 children with severe chronic bilirubin encephalopathy, including a former preterm infant without marked hyperbilirubinemia VIDEO.
106. Persistent neonatal hyperbilirubinemia resulting from Gilbert's syndrome in association with RhD hemolytic disease.
107. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature.
108. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.
109. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector.
110. Hyperbilirubinemia guidelines in newborn infants.
111. Association of transcutaneous bilirubin testing in hospital with decreased readmission rate for hyperbilirubinemia.
112. Reduction in hospital readmission rates for hyperbilirubinemia is associated with use of transcutaneous bilirubin measurements.
113. Neonatal hyperbilirubinemia and risk of autism spectrum disorders.
114. Management of neonatal hyperbilirubinemia.
115. Hyperbilirubinemia guidelines and unintended harms.
116. Management of hyperbilirubinemia: quality of evidence and cost.
117. Bilirubin dosage in cord blood: could it predict neonatal hyperbilirubinemia?
118. Hyperbilirubinemia benchmarking.
119. Management of hyperbilirubinemia in newborns: measuring performance using a benchmarking model.
120. Evaluation of two guidelines for the management of hyperbilirubinemia in newborn babies weighing less than 2,000 g.
121. Hyperbilirubinemia among African American, glucose-6-phosphate dehydrogenase-deficient neonates.
122. An evidence-based review of important issues concerning neonatal hyperbilirubinemia.
123. Hyperbilirubinemia benchmarking.
124. Intervention recommendations for neonatal hyperbilirubinemia.
125. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
126. Cerebral metabolism in severe neonatal hyperbilirubinemia.
127. Hyperbilirubinemia and kernicterus: 50 years later.
128. Efficacy of oral phenobarbitone in term "at risk" neonates in decreasing neonatal hyperbilirubinemia: a randomized double-blinded, placebo controlled trial.
129. Incidence, course, and prediction of hyperbilirubinemia in near-term and term newborns.
130. Neonatal hyperbilirubinemia due to hereditary spherocytosis.
131. Persistant unconjugated hyperbilirubinemia in an infant with crigler-najjar syndrome type I.
132. Treatment of neonatal hyperbilirubinemia
133. Familial hyperbilirubinemia in ABO-incompatible neonates.
134. Applying the "10 simple rules" of the institute of medicine to management of hyperbilirubinemia in newborns.
135. Management of hyperbilirubinemia in newborns: measuring performance by using a benchmarking model.
136. Is hyperbilirubinemia a component or just a coincidence of familial mediterranean fever: a case report and review of the literature.
137. Tin-mesoporphyrin in the treatment of severe hyperbilirubinemia in a very-low-birth-weight infant.
138. Risk factors for hyperbilirubinemia and gallstones in Chinese patients with b thalassemia syndrome.
139. Gly71Arg mutation of the bilirubin UDP-glucuronosyltransferase 1A1 gene is associated with neonatal hyperbilirubinemia in the Japanese population.
140. Hemolysis and hyperbilirubinemia in an African American neonate heterozygous for glucose-6-phosphate dehydrogenase deficiency.
141. Hyperbilirubinemia in the term newborn.
142. Treatment of hyperbilirubinemia pharmacologic approach SnMP(tin-mesoporphyrin).
143. Jaundice technologies: prediction of hyperbilirubinemia in term and near-term newborns.
144. Prediction of hyperbilirubinemia in near-term and term infants.
145. Genetic interactions in the pathogenesis of neonatal hyperbilirubinemia: Gilbert's Syndrome and glucose-6-phosphate dehydrogenase deficiency.
146. Mechanism of indinavir-induced hyperbilirubinemia.
147. Cerebral oximetry and hyperbilirubinemia.
148. Hyperbilirubinemia during quinupristin-dalfopristin therapy in liver transplant recipients: correlation with available liver biopsy results.
149. A patient with exacerbation of idiopathic pulmonary fibrosis which was resolved probably due to the coexisting hyperbilirubinemia?
150. Plasma exchange for hyperbilirubinemia following implantation of a left ventricle assist system: a case report.
151. Hyperbilirubinemia in term newborn infants. The Canadian Paediatric Society.
152. Managing hyperbilirubinemia in term newborn infants.
153. Re: Management of hyperbilirubinemia in term newborn infants.
154. Co-inherited Gilbert's syndrome: a factor determining hyperbilirubinemia in homozygous beta-thalassemia.
155. Approach to the management of hyperbilirubinemia in term newborn infants.
156. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome.
157. Correction of congenital hyperbilirubinemia in homozygous Gunn rats by xenotransplantation of hamster livers.
158. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia.
159. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation.
160. Assessing liver function and hyperbilirubinemia in the newborn. National Academy of Clinical Biochemistry.
161. Single x double phototherapy for the treatment of hyperbilirubinemia in high risk newborn infants.
162. Xenotransplantation of hamster liver into Gunn rats reserves congenital hyperbilirubinemia.
163. Indications of phototherapy for full term newborn infants with non-hemolytic hyperbilirubinemia: a critical analysis.
164. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice.
165. Two distinct mechanisms for bilirubin glucuronide transport by rat bile canalicular membrane vesicles. Demonstration of defective ATP-dependent transport in rats (TR-) with inherited conjugated hyperbilirubinemia.
166. Hyperbilirubinemia associated with sepsis in the elderly.
167. Investigation of Newborn Hyperbilirubinemia: Helping family physicians indentify newborns at risk.
168. Hyperbilirubinemia.
169. Phototherapy for neonatal hyperbilirubinemia.
170. Effect of educational program and interview on adoption of guidelines for the management of neonatal hyperbilirubinemia.
171. Contribution of delta bilirubin to the interpretation of hyperbilirubinemia in the horse - a pilot study.
172. Defective ATP-dependent bile canalicular transport of organic anions in mutant (TR-) rats with conjugated hyperbilirubinemia.
173. Bartter's syndrome associated with indirect hyperbilirubinemia: a possible clinical variety.
174. Defective biliary secretion of bile acid 3-O-glucuronides in rats with hereditary conjugated hyperbilirubinemia.
175. Hepatobiliary transport of glutathione and glutathione conjugate in rats with hereditary hyperbilirubinemia.
176. Hyperbilirubinemia does not interfere with hemoglobin saturation measured by pulse oximetry.
177. Effects of rokitamycin on young rats with hyperbilirubinemia--determination of unbound and brain bilirubin levels and examination for localized yellow discoloration of brain tissue.
178. A case of hyperbilirubinemia during treatment with chenodeoxycholic acid.
179. Use of phototherapy for neonatal hyperbilirubinemia. Fetus and Newborn Committee, Canadian Paediatric Society.
180. Sn-protoporphyrin inhibition of fetal and neonatal brain heme oxygenase. Transplacental passage of the metalloporphyrin and prenatal suppression of hyperbilirubinemia in the newborn animal.
181. Studies on the mechanism of Sn-protoporphyrin suppression of hyperbilirubinemia. Inhibition of heme oxidation and bilirubin production.
182. Hyperbilirubinemia in Indian newborns.
183. Influence of a phototherapy unit on detection of neonatal jaundice and hyperbilirubinemia.
184. Conjugated hyperbilirubinemia in an autopsy case with myocardial infarction and sepsis.
185. An experimental model of postnatal jaundice in the suckling rat. Suppression of induced hyperbilirubinemia by Sn-protoporphyrin.
186. Hyperbilirubinemia in sick cattle.
187. Tin-protoporphyrin suppression of hyperbilirubinemia in mutant mice with severe hemolytic anemia.
188. Hyperbilirubinemia in patients with decompensated chronic Chagas cardiomyopathy.
189. Suppression of hyperbilirubinemia in the rat neonate by chromium-protoporphyrin. Interactions of metalloporphyrins with microsomal heme oxygenase of human spleen.
190. Hyperbilirubinemia in Inuit neonates.
191. Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation.
192. Spurious hyperbilirubinemia in uremic patients on propranolol therapy.
193. Hyperbilirubinemia in inflammatory pancreatic disease: natural history and management.
194. Animal model of human disease. Increased sensitivity to polychlorinated biphenyls. Animal model: gunn rats with hereditary hyperbilirubinemia.
195. Disturbed bone marrow cell proliferation in primary shunt hyperbilirubinemia.
196. Animal model of human disease. Crigler-Najjar Syndrome. Animal model: hereditary nonhemolytic unconjugated hyperbilirubinemia in Gunn rats.
197. Renal radial fibrosis in mutant Southdown sheep with congenital hyperbilirubinemia.
198. Lesions in Southdown sheep with hereditary hyperbilirubinemia.
199. Blood coagulation valves in normal sheep and in two mutant strains with hyperbilirubinemia.
200. Phototherapy in the treatment of hyperbilirubinemia.
201. Effect of sodium phenobarbital on bilirubin metabolism in an infant with congenital, nonhemolytic, unconjugated hyperbilirubinemia, and kernicterus.
202. TRANSIENT FAMILIAL NEONATAL HYPERBILIRUBINEMIA.
203. Prolonged neonatal unconjugated hyperbilirubinemia associated with breast feeding and a steroid, pregnane-3(alpha), 20(beta)-diol, in maternal milk that inhibits glucuronide formation in vitro.
204. Hyperbilirubinemia in a newborn infant probably related to cephalhematoma.
205. Chronic unconjugated hyperbilirubinemia without overt signs of hemolysis in adolescents and adults.
206. Viral hepatitis. A study of hyperbilirubinemia with acholuria in convalescence.
207. Extraneural lesions associated with neonatal hyperbilirubinemia and kernicterus.
208. Influence of cortisone and prednisolone on hyperbilirubinemia.
209. Physiological hyperbilirubinemia in the newborn and the reservoir function of the spleen.